A nutraceutical market report from UBM Canon Data Products estimates that the U.S. nutraceutical market will reach $180 billion in 2017.
A nutraceutical market report from UBM Canon Data Products estimates that the U.S. nutraceutical market will reach $180 billion in 2017, maintaining a compound annual growth rate of over 7% through 2015.
Titled “Nutraceuticals and Vitamins Review and Outlook 2011,” the report cites an aging population, increased prevalence of serious diseases, and ongoing interest in preventative medicine as reasons for market growth.
The report also highlights emerging global markets such as India, where nutraceutical sales are projected to at least double between now and 2015.
UBM Canon Data Products provides financial, company, and product statistical data for a variety of other industries, including pharmaceutical biotechnology and medical devices.
The Nutritional Outlook Podcast Episode 35: Prioritizing Women's Health Research and Innovation
October 28th 2024On this month's episode of the Nutritional Outlook Podcast, Cepham's founder and president, Anand Swaroop, discusses the company's recent announcement to prioritize women's health research and innovation.
The Nutritional Outlook Podcast Episode 34: Demystifying Prebiotics and Postbiotics
September 30th 2024In this episode of the Nutritional Outlook Podcast we are looking back on a webcast Nutritional Outlook hosted in May, called “Demystifying the Prebiotic and Postbiotic Markets.” During that event, Sandra Saville, director of education and communication for the International Probiotics Association and Dr. Jessica A. Younes, scientific director of the International Probiotics Association debunked myths about prebiotic and postbiotics, and defined the respective categories to help manufacturers better understand how to responsibly formulate and market prebiotic and postbiotic products.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.